Sino Biopharmaceutical’s TDI01 Receives Clinical Trial Approval for COVID-19
China’s Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Beijing Tide Pharmaceutical Co....
HKG: 1177
Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Jiangsu Chia Tai Tianqing...
F-star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Amid CFIUS Review
UK-based biotech F-star Therapeutics Inc. (NASDAQ: FSTX) announced in a stock exchange press release that...
invoX Pharma Extends Tender Offer for F-star Therapeutics to September 19
invoX Pharma Ltd, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177), announced that...
Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA)...